301685-23-4

Upstream product

• 2258-42-6 formyl acetic anhydride 
• 234768-83-3 (2R)-2-({[(phenylmethyl)oxy]amino}methyl)hexanoic acid 
• 478912-43-5 4-benzyl-3-[2-(benzyloxyamino-methyl)-hexanoyl]-oxazolidin-2-one 
• 478912-40-2 (4S)-3-(2-methylene-1-oxohexyl)-4-(phenylmethyl)-2-oxazolidinone 
• 143965-32-6 (4S)-3-hexanoyl-4-(phenylmethyl)-1,3-oxazolidin-2-one 
• 72773-04-7 N-formylbenzotriazole 
• 29601-98-7 N-benzylhydroxylamine hydrochloride 
• 668485-39-0 (4S)-3-[(2R)-2-(hydroxymethyl)hexanoyl]-4-(phenylmethyl)-1,3-oxazolidin-2-one 
• 142-61-0 Hexanoyl chloride 
• 64-18-6 formic acid 
• 2985-32-2 butylmalonic acid monoethyl ester 
• 58243-89-3 (±)-2-butyl-3-hydroxypropionic acid 
• 2612-26-2 2-butylpropane-1,3-diol 
• 676127-84-7 (3R)-3-butyl-1-[(phenylmethyl)oxy]-2-azetidinone 

Downstream Products

• 235786-03-5 (R)-2-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid ((S)-1-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide 
• 609366-93-0 (R)-2-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid ((S)-1-dimethylcarbamoyl-2-methyl-propyl)-amide 
• 609366-99-6 (R)-2-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid ((1S,2S)-1-dimethylcarbamoyl-2-methyl-butyl)-amide 
• 301684-72-0 2(R)-[(N-benzyloxy-N-formylamino)-methyl]-hexanoic acid pentafluorophenyl ester 
• 609367-19-3 (S)-1-{(R)-2-[(Benzyloxy-formyl-amino)-methyl]-hexanoyl}-pyrrolidine-2-carboxylic acid dimethylamide 
• 609366-92-9 (R)-2-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid ((S)-1-dimethylcarbamoyl-ethyl)-amide 
• 1382936-35-7 N-(benzo[d][1,3]dioxol-5-yl)-2-[(S)-1-[(R)-2-[[N-(benzyloxy)formamido]methyl]hexanamido]-2-methylpropyl]oxazole-4-carboxamide 
• 1382936-34-6 2-[(S)-1-[(R)-2-[[N-(benzyloxy)formamido]methyl]hexanamido]-2-methylpropyl]-N-(3,4-difluorophenyl)oxazole-4-carboxamide 
• 1382936-21-1 (R)-2-[[N-(benzyloxy)formamido]methyl]-N-[(S)-2-methyl-1-[4-(piperidine-1-carbonyl)oxazol-2-yl]propyl]hexanamide 
• 1382936-17-5 2-[(S)-1-[(R)-2-[[N-(benzyloxy)formamido]methyl]hexanamido]-2-methylpropyl]-N,N-diethyloxazole-4-carboxamide 
• 1382936-36-8 2-[(S)-1-[(R)-2-[[N-(benzyloxy)formamido]methyl]hexanamido]-2-methylpropyl]-N-(5-fluoropyridin-2-yl)oxazole-4-carboxamide 
• 1382936-33-5 2-[(S)-1-[(R)-2-[[N-(benzyloxy)formamido]methyl]hexanamido]-2-methylpropyl]-N-(4-fluorophenyl)oxazole-4-carboxamide 
• 1382936-28-8 2-[(S)-1-[(R)-2-[N-(benzyloxy)formamidomethyl]hexanamido]-2-methylpropyl]-N-p-tolyloxazole-4-carboxamide 
• 1281973-29-2 C₂₅H₃₁FN₄O₆ 

Relevant academic research and scientific papers

Peptide deformylase inhibitors

The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.

PEPTIDE DEFORMYLASE INHIBITORS

The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhi-bition of bacterial peptide deformylase (PDF) activity

Synthesis and in vitro antibacterial activity of oxazolidine LBM-415 analogs as peptide deformylase inhibitors

The drug resistant bacteria pose a severe threat to human health. The increasing resistance of those pathogens to traditional antibacterial therapy renders the identification of new antibacterial agents with novel antibacterial mechanisms an urgent need.

Peptide deformylase inhibitors of Mycobacterium tuberculosis: Synthesis, structural investigations, and biological results

Bacterial peptide deformylase (PDF) belongs to a subfamily of metalloproteases catalyzing the removal of the N-terminal formyl group from newly synthesized proteins. We report the synthesis and biological activity of highly potent inhibitors of Mycobacterium tuberculosis (Mtb) PDF enzyme as well as the first X-ray crystal structure of Mtb PDF. Structure-activity relationship and crystallographic data clarified the structural requirements for high enzyme potency and cell based potency. Activities against single and multi-drug-resistant Mtb strains are also reported.

PDF INHIBITORS

The invention relates to novel compounds that are inhibitors of peptidyl deformylase (PDF). The compounds are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as MMPs. Methods of preparation and uses of the compounds are also disclosed.

ANTIBACTERIAL AGENTS

Selected compounds of formula (I) are antibacterial agents: formula (I) wherein R2 represents a substituted or unsubstituted C1-C6 alkyl, cycloalkyl (C1-C6 alkyl)- or aryl (C1-C6 /SUB

Antibacterial agents

Compounds of formula (II) are antibacterial agents wherein Q represents a radical of the formula: —N(OH)CH(═O) or the formula: —C(═O)NH(OH); R1 represents hydrogen, C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms, or, except when Q is a radical of the formula: —N(OH)CH(═O), a hydroxy, C1-C6 alkoxy, C1-C4 alkenyloxy, amino, C1-C4 alkylamino, or di-(C1-C6 alkyl)amino group; R2 represents a substituted or unsubstituted C1-C6 alkyl, cycloalkyl(C1-C6 alkyl)- or aryl(C1-C6 alkyl)-group; and A represents a group of formula (IIA), or (IIB) wherein R4 represents the side chain of a natural or non-natural alpha amino acid, and R5 and R6 when taken together with the nitrogen atom to which they are attached form a saturated heterocyclic first ring of 5 to 7 atoms as specified in the description.

Antimicrobial agents

Compounds of formula (I) are antibacterial agents: wherein Z represents a radical of formula —N(OH)CH(=O) or of formula —C(=O)NH(OH), and R1-R4 are as defined in the specification. A method for the treatment of bacterial or protozoal infections in humans and non-human mammals, which comprises administering to a subject suffering such infection an antibacterially or antiprotozoally effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof.

Asymmetric synthesis of BB-3497 - A potent peptide deformylase inhibitor

By screening a library of metalloenzyme inhibitors, the N-formyl-hydroxylamine derivative BB-3497 was identified as a potent inhibitor of Escherichia coli peptide deformylase with antibacterial activity both in vitro and in vivo. The homochiral synthesis of BB-3497, involving a novel asymmetric Michael addition reaction is described.